{"id":"NCT01024608","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Beclomethasone Dipropionate Hydrofluoroalkane (BDP HFA) Nasal Aerosol in Subjects 12 Years of Age and Older With SAR","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-12-31","primaryCompletion":"2010-02-28","completion":"2010-02-28","firstPosted":"2009-12-03","resultsPosted":"2012-05-23","lastUpdate":"2021-12-03"},"enrollment":340,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Seasonal Allergic Rhinitis","Hay Fever"],"interventions":[{"type":"DRUG","name":"Beclomethasone dipropionate","otherNames":["QNASL(TM)"]},{"type":"DRUG","name":"Placebo Nasal Aerosol","otherNames":[]}],"arms":[{"label":"BDP HFA 320 µg/day","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to assess the efficacy and safety of an investigational nasal aerosol compared with placebo nasal aerosol in the treatment of seasonal allergic rhinitis.","primaryOutcome":{"measure":"Change From Baseline in Average Subject-Reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period","timeFrame":"Baseline (Days -3 to 0), and Days 1-15","effectByArm":[{"arm":"BDP HFA 320 µg/Day","deltaMin":-2,"sd":0.16},{"arm":"Placebo","deltaMin":-1,"sd":0.15}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":["23026180"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":167},"commonTop":["Nasal discomfort"]}}